Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

GDF-15 and FGF-23 are associated with mortality in type 2 diabetic patients with microalbuminuria

Publikation: KonferencebidragKonferenceabstrakt til konferenceForskning

  1. 53rd Annual Meeting of the European Association for the study of Diabetes EASD

    Aktivitet: Deltagelse i eller arrangering af en begivenhedOrganisation af og deltagelse i konference

  1. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Essential Branched-Chain Amino Acids and Ribonic Acid Are Associated with Cardiorenal Events in Type 1 Diabetes

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Vis graf over relationer
Background and aims: We evaluated two biomarkers (growth differentiation factor 15 (GDF-15) and (FGF-23) reflecting different aspects of renal pathophysiology as determinants of decline in estimated glomerular filtration rate (eGFR), incident cardiovascular disease (CVD) and all-cause mortality in patients with type 2 diabetes (T2D) and microalbuminuria, but without clinical coronary artery disease. Materials and methods: Prospective study including 200 patients. GDF-15 and FGF-23 were measured at baseline and were available in 191 patients. Adjusted Cox models included sex, age, LDL cholesterol, smoking, HbA1c, creatinine, systolic blood pressure and urine albumin excretion rate (UAER). A decline in eGFR of >30%, which has recently been suggested as a valid renal outcome, at any time point during follow-up was the predefined endpoint of CKD progression. Hazard ratios (HR) are provided per 1 SD increment of log-transformed values of the urinary biomarkers. Results: Patients were (± SD) 59 ± 9 years old, eGFR 91.1 ± 18.3 ml/min/1.73m2 and UAER (IQR) 103 (39-230) mg/24-h. During a median 6.1 years follow-up, there were 40 incident CVD events and 26 deaths and a total of 42 patients reached the predefined CKD progression endpoint after 4.9 years (median). Higher GDF-15 was a determinant of decline in eGFR >30% in unadjusted (HR (95% CI) 1.7 (1.3-2.4); p=0.001) and adjusted (HR 1.7 (1.1-2.5); p=0.018) models, a predictor of CVD in the unadjusted model (HR 1.4 (1.0-1.9); p=0.034) but not in the adjusted model (HR 1.3 (0.9-1.8); p=0.25) and of all-cause mortality in unadjusted (HR 1.8 (1.3-2.6); p<0.001) and adjusted (HR 1.9 (1.2-2.9); p=0.003) models. Higher FGF-23 was not associated with decline in eGFR >30% or CVD, but was associated with all-cause mortality in unadjusted (HR 1.5 (1.1-2.0); p=0.010) and adjusted (HR 1.6 (1.1-2.2); p=0.011) models. Conclusion: In patients with T2D and microalbuminuria, GDF-15 was independently associated with decline in kidney function and all-cause mortality, and higher FGF-23 was associated with all-cause mortality.
OriginalsprogEngelsk
Publikationsdato12 sep. 2017
Antal sider1
StatusUdgivet - 12 sep. 2017
Begivenhed53rd Annual Meeting of the European Association for the study of Diabetes EASD - International Fair of Lisbon and MEO Arena, Rua do Bojador, Parque das Nações, Lisabon, Portugal
Varighed: 11 sep. 201715 sep. 2017
https://www.easd.org/annual-meeting/easd-2017.html

Konference

Konference53rd Annual Meeting of the European Association for the study of Diabetes EASD
LokationInternational Fair of Lisbon and MEO Arena, Rua do Bojador, Parque das Nações
LandPortugal
ByLisabon
Periode11/09/201715/09/2017
Internetadresse

Begivenhed

53rd Annual Meeting of the European Association for the study of Diabetes EASD

11/09/201715/09/2017

Lisabon, Portugal

Begivenhed: Konference

ID: 52001252